Exelixis (EXEL) Receivables - Other (2010 - 2021)
Exelixis (EXEL) posted quarterly Receivables - Other of $9.7 million for Q3 2021, down 29.36% year-over-year from $13.8 million in Q3 2020, and down 29.36% quarter-over-quarter from $13.8 million in Q3 2020.
Exelixis (EXEL) Receivables - Other (2010 - 2021) Analysis & Trends
Exelixis' Receivables - Other history runs 10 years deep, the most recent figure standing at $9.7 million for Q3 2021.
- In Q3 2021, Receivables - Other fell 29.36% year-over-year to $9.7 million; the TTM figure through Jul 2021 stood at $9.7 million (down 29.36% YoY), while the FY2020 annual figure was $1.1 million, down 75.92% from the prior year.
- Receivables - Other for Q3 2021 stood at $9.7 million, down from $13.8 million in the prior quarter.
- The five-year high for Receivables - Other was $31.8 million in Q1 2018, with the low at -$8.7 million in Q1 2019.
- The 5-year median for Receivables - Other is $11.1 million (2019), against an average of $10.4 million.
- The sharpest annual moves came in 2019 and 2020: Receivables - Other plunged 127.45% in 2019, then gained 11.38% in 2020.
- Exelixis' Receivables - Other stood at $3.9 million in 2017, then tumbled by 62.18% to $1.5 million in 2018, then jumped by 837.57% to $13.8 million in 2019, then slipped by 0.01% to $13.8 million in 2020, then dropped by 29.36% to $9.7 million in 2021.
- Business Quant data shows EXEL's Receivables - Other at $9.7 million in Q3 2021, $13.8 million in Q3 2020, and $1.1 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 2, 2021 | 9.75 Mn |
| Jul 2, 2021 | 9.75 Mn |
| Jul 3, 2020 | 13.80 Mn |
| Jul 3, 2020 | 13.80 Mn |
| Jan 3, 2020 | 1.06 Mn |
| Jan 3, 2020 | 1.06 Mn |
| Sep 27, 2019 | 13.80 Mn |
| Sep 27, 2019 | 13.80 Mn |
| Jun 28, 2019 | 12.39 Mn |
| Jun 28, 2019 | 12.39 Mn |
| Mar 29, 2019 | -8.74 Mn |
| Mar 29, 2019 | -8.74 Mn |
| Dec 28, 2018 | 1.47 Mn |
| Dec 28, 2018 | 1.47 Mn |
| Sep 28, 2018 | 24.49 Mn |
| Sep 28, 2018 | 24.49 Mn |
| Mar 30, 2018 | 31.84 Mn |
| Mar 30, 2018 | 31.84 Mn |
| Dec 29, 2017 | 3.89 Mn |
| Dec 29, 2017 | 3.89 Mn |